Citalopram Hydrobromide Tablets for Depressive Disorder

• Sample: Free
• Transport Package: Box
• Specification: 20mg*12tab/box
• Trademark: FUL
• Origin: China
• Model NO.: FC078
• Production Capacity: 10000PCS/

Product Description

Item Name:Citalopram hydrobromide tablets
Molecular formula:C₂₀H₂₂FN₂O ·HBr

Item Description

Item nanme:Citalopram hydrobromide tablets
Item character:The product is yellow

Indication:
Depressive disorder (endogenous and non endogenous depression).

Item specifications: 20mg*12tab/box

Usage and dosage:Adults: take 20mg once a day.
According to the response of individual patients, the dose can be increased, and the maximum dose is 40 mg per day.
Duration of treatment
Antidepressant effect usually appears after 2-4 weeks. Antidepressant treatment belongs to symptomatic treatment, so it must be continued for an appropriate long time (usually to 6 months after recovery) to prevent recurrence. In patients with recurrent depression, maintenance therapy may need to be continued for many years to prevent recurrence.
Elderly patients (> 65 years old)
Elderly patients should reduce the dose to half of the recommended dose, i.e. 10-20 mg per day. The recommended maximum dose is 20 mg per day.
Children and adolescents (< 18 years old)
This product is not suitable for children and teenagers under 18 years old.
Patients with decreased renal function
Patients with mild to moderate renal impairment do not need dose adjustment. It should be used with caution in patients with severe renal impairment (creatinine clearance less than 30 ml / min, see pharmacokinetics).
Patients with decreased liver function
It is recommended that patients with mild or moderate liver injury use an initial dose of 10 mg per day for the first two weeks of treatment. Depending on the individual patient's response, the maximum dose can be increased to 20 mg per day. Patients with severe liver dysfunction should be cautious in dose adjustment.
Patients with weak metabolism of CYP2C19
For patients known to have weak CYP2C19 metabolism, an initial dose of 10 mg per day is recommended for the first two weeks of treatment. Depending on the individual patient's response, the maximum dose can be increased to 20 mg per day.
Withdrawal
This product should avoid sudden withdrawal. When the drug is stopped, the dose should be gradually reduced within at least 1-2 weeks in order to reduce the risk of drug withdrawal reaction. If intolerable symptoms appear after dose reduction or treatment discontinuation, the previous prescribed dose can be considered. After that, the doctor can continue to reduce the dose, but at a more gentle rate.
Method of administration: oral once a day.
This product can be taken at any time of the day, regardless of food intake.

Adverse reactions
The adverse reactions observed in this product are usually mild and lasting for a short time. The most frequent occurrence occurs in the first to second weeks of treatment, and then gradually alleviates. Adverse reactions are selected from the preferred terms catalogue of the ICH International Dictionary of medical terms (MedDRA).
The following adverse reactions were observed to be dose-related: sweating, dry mouth, insomnia, sleepiness, diarrhea, nausea and fatigue.
The following table shows the percentage of adverse drug reactions observed in patients with double-blind placebo-control trials ≥ 1 per cent or after market, with regard to SSRIs (selective serotonin reuptake inhibitors) and / or citalopram hydrobromide. Frequency definition: very common (≥ 1/10); Common (≥ 1/100, < 1/10); Occasionally (≥ 1/1000, 1/100); Rare (≥ 1/10000, < 1/1000); It is very rare (< 1 / 10000), unknown (cannot be estimated based on existing data).
fracture
Epidemiological studies, mainly in patients 50 and over, have shown that the risk of fracture in patients receiving SSRIs (noradrenaline and 5-hydroxytryptamine dual inhibitors) and TCAS (tricyclic antidepressants) is increased. The mechanism that causes this risk is unknown.
QT interval extension
During the post market period, QT interval extension and ventricular arrhythmia were reported, including tip torsion ventricular tachycardia, mainly in women, hypokalemia patients, or patients with QT interval extension with other heart disease in advance.
Symptoms of drug withdrawal observed at the end of SSRI treatment
The drug withdrawal (especially sudden stop) of this product usually produces drug stopping symptoms, and the most frequently reported reactions are dizziness, sensory disorder (including sensory abnormality), sleep disorder (including insomnia and multiple dreams), agitation or anxiety, nausea and / or vomiting, tremor, confusion, sweating, headache, diarrhea, palpitation, emotional instability, irritability and visual impairment. These adverse events are usually mild to moderate and self limiting, however, may be severe and / or long-term in some patients. Therefore, it is suggested that the drug should be stopped gradually by gradually reducing the dose when the treatment of this product is no longer needed.

Taboo:
1. It is forbidden for those who are allergic to the active ingredients and / or any excipients in this product.
2. Monoamine oxidase inhibitors (MAOIs)
Patients receiving monoamine oxidase inhibitor (MAOIs) (including daily dose of selegiline exceeding 10mg) should not take this product at the same time during the 14 days after the withdrawal of irreversible MAOI, or should not take this product within a specified period of time after the withdrawal of Rima specified in the prescription of reversible MAOI (Rima). MAOIs should not be given during the 14 days after withdrawal.
3. It is forbidden to use linezolid in combination with linezolid, unless there is a device to closely observe and monitor blood pressure. See the drug interaction section for details.
4. Drug combination with pimozide is prohibited. See drug interaction for details.
5. It is forbidden to use this product in patients with known QT interval prolongation or congenital QT syndrome.

Matters needing attention:
1. drug stopping reaction
After listing, there are some spontaneous reports of adverse events after drug withdrawal, especially in sudden stop of drugs. It can be seen from time to time that: emotional irritability, irritability, agitation, dizziness, abnormal feeling (electric shock), anxiety, blurred consciousness, headache, laziness, emotional instability, insomnia, mania, tinnitus and epilepsy. The above performance is generally self limiting, and there are also reports of serious drug stop reaction.
When the patient stops the product, it is necessary to monitor these possible symptoms of stopping the drug. It is recommended to reduce the dosage gradually to avoid sudden stop of the drug. If intolerable symptoms occur during drug reduction and withdrawal, it is possible to consider returning to the previous treatment dose, and then the doctor will reduce the drug at a slower rate.
2. abnormal bleeding
There have been reports of subcutaneous bleeding time and / or bleeding abnormalities when SSRIs is used, such as ecchymosis, gynecological bleeding, gastrointestinal bleeding, and other skin or mucosal bleeding. Caution should be taken in patients taking SSRIs, especially in combination with active substances known to affect platelet function or other active substances that may increase the risk of bleeding, and in patients with a history of bleeding diseases.
3. hyponatremia
Hyponatremia is rarely reported with SSRI drugs, which may be caused by abnormal secretion of SIADH, and will normally return to normal at the end of treatment. In particular, elderly women may be prone to such risks.
4. sit still / psychomotor restlessness
The use of ssris/snris has been considered to be related to the formation of sit still, which is characterized by subjective unpleasant or disturbing restlessness, which requires constant exercise and can not sit quietly. This is most likely to occur in the first few weeks of treatment. In patients with these symptoms, increasing doses can be harmful.
5. mania
Patients with manic depression may turn into manic episodes. Patients who have been turned into manic episodes should stop using this product.
6. epilepsy
Epilepsy is a potential risk in the use of antidepressants. Patients with epilepsy should stop using this product. In patients with unstable epilepsy, we should avoid using this product, and the patients who have been controlled should be carefully monitored. If the frequency of seizures increases, stop using the product.
7. diabetes
In patients with diabetes, the use of certain SSRI for treatment may change blood glucose control. Adjustments may be required for the dose of insulin and / or oral hypoglycemic drugs.
8. ECT (electric shock therapy)
The clinical experience of SSRIs and ECT treatment is limited, so it should be cautious.
9. St. John's grass
Adverse reactions may be more common during the combination of this product and herbal preparations containing St. John's (Forsythia perforatum). Therefore, this product and St. John's herbal preparation should not be taken simultaneously.
10. mental illness
The treatment of the psychotic patients with depression may increase the symptoms of mental illness. The drug should be used under the guidance of the doctor.
11. auxiliary materials (add this content according to the composition of each auxiliary material as appropriate)
The auxiliary material of this product contains lactose hydrate. This product is not used in patients with rare genetic galactose intolerance, and patients with lactase deficiency or glucose galactose malabsorption.
12. impact on the ability of driving and operating the machine
This product has a slight or moderate impact on the ability to start and use the machine.
Psychoactive drugs can reduce the ability to judge and respond to emergencies. Patients should be informed of these impacts and their ability to drive or operate the machine may be affected.
13. please put it in a place that is not easy for children.

Medication for pregnant and lactating women:
gestation
Published data on pregnant women (more than 2500 exposure results) show no teratogenic fetal / neonatal toxicity. However, this product should not be used during pregnancy unless there is a clear need and only after careful consideration of the risks / benefits.
If the mother continues to use this product until late pregnancy (especially in late pregnancy), the newborn should be observed. Sudden discontinuation of medication should be avoided during pregnancy.
After using SSRI / SNRI in late pregnancy, the following symptoms may appear in newborns: respiratory distress, cyanosis, asphyxia, convulsion, temperature instability, eating difficulty, vomiting, hypoglycemia, hypertonia, hypotonia, hyperreflexia, tremor, nerve hypersensitivity, stress, drowsiness, continuous crying, drowsiness and sleep difficulty. These symptoms may be caused by serotonin effect or withdrawal symptoms. In most cases, complications begin immediately or shortly after delivery (< 24 hours).
Epidemiological data suggest that the use of SSRIs during pregnancy (especially in late pregnancy) may increase the risk of persistent pulmonary hypertension (PPHN) in neonates. The observed risk was about 5 per 1000 pregnancies. In the general population, every 1000 cases of pregnancy will appear about 1-2 cases.
lactation
Citalopram is secreted into breast milk. It is estimated that breastfeeding infants will receive about 5% of the weight related mother's daily dose in mg / kg. No or only mild events were observed in infants. However, there is not enough information on the assessment of children's risk. It is recommended to use it with caution.

FAQ
1.who are we?
We are based in Fujian, China, start from 2000,sell to North America(40.00%),Southeast Asia(25.00%),Western Europe(25.00%),Africa(10.00%).There are total about 50 people in our office.

2. how can we guarantee quality?
Always a pre-production sample before mass production;
Always final Inspection before shipment;

3.what can you buy from us?
Pharmaceutical production lines,Intermediates,APIs,Finished Drug Preparations & Vaccines.

4. why should you buy from us not from other suppliers?
We have our own manufacture factories and one professional sales team working for the clients all over the world.

5. what services can we provide?
Accepted Delivery Terms: FOB,CIF,EXW,DDP,Express Delivery;
Accepted Payment Currency:USD,EUR,CAD,AUD,GBP,CNY;
Accepted Payment Type: T/T,L/C,PayPal,Western Union;
Language Spoken:English,Chinese,Japanese

Our Ddvantage:
1. Quick delivery
2. Online payment
3. Quality assurance
4. Welcome big order
5. After-sales service 24 hours
6. Competitive advantage products
7. Our value information is "Quality is our culture"
8. Work with us to provide you with secure funds, your business is securely protected, our advantages

Our Service
a)  Free amples can be provided.
b) Guide customers through professional technology and teach them how to use our products after sale
c) Determine the lowest price of high-quality products
1. Skilled experience: Our company is a leading manufacturer of professional production in China pharmaceutical field for many years.
2. The highest quality: to ensure high quality, once any problems are found, the package will be re-shipped for you.
3. Safe transportation: by air express (FedEx, UPS, DHL, EMS). It is recommended that you choose the most professional freight forwarder.
4. Fast delivery: We have stock, so once payment is received, we can deliver quickly.
5. Quality service: We will provide you with enthusiastic after-sales service. If you have any questions, we will reply to youwithin 24 hours.
6. Competitive price: discounts will be obtained when making large orders.

Our Manufacture Factory
Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd is a comprehensive enterprise which integrates R & D, production and construction of pharmaceutical production equipments, development and transfer of biotechnology, and cooperative production and sales of drugs and vaccines. The self-developed pharmaceutical production equipment branded FUL has been put into operation in many well-known pharmaceutical enterprises  CSPC and also cooperates with many well-known pharmaceutical enterprises in production and sales, including pharmaceutical intermediates, APIs and finished drug preparations.

Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd business radiates to all levels, including direct supply cooperation with government departments and industry representatives, as well as establishing supply cooperation relationship with retail industry. We supply high quality, safe and effective medicines and medical equipment to governments, hospitals, clinics and licensed pharmacies in different countries with timely and effective services at reasonable prices.

At present Fuzhou FUL Fluid Equipment & Pharmaceutical Co., Ltd has the authorization to sell its intermediates and APIs,and has the authorizations of CSPC & HUABEI PHARM sell its finished drug preparations;then FUL is the only manufacture in China which can supply the complete service from pharmaceutical produciton lines,intermediates and APIs to finished drug preparations and vaccines.Then we are seeking the professional pharmaceutical enterprices to work together for further cooperations.




Factory View


Our Products


Our Business